FMC launches strategic review to explore sale, asset sales and $1B debt reduction

FMC launches strategic review to reshape business and balance sheet

Board-authorized review

FMC Corporation says its board has authorized a review of strategic options, including the possibility of a sale, as the crop-protection company seeks to unlock shareholder value and better position its growth and core portfolios for long-term success. The board frames the review as preliminary and does not assure it will lead to a transaction, while Chairman, CEO and President Pierre Brondeau says the company will continue executing its operational priorities during the process. Management stresses the review is intended to explore how additional capital or structural change could accelerate investment in new technologies and strengthen competitive positioning.

Operational priorities tied to the review

FMC outlines a set of 2026 priorities that run in parallel with the strategic review, led by a targeted $1.0 billion debt paydown through asset sales and licensing agreements and the previously announced sale of its India commercial business. The company is also focusing on improving competitiveness of its legacy core portfolio and managing the post-patent transition for its key insecticide Rynaxypyr®, which is driving expected pricing pressures. FMC says it will advance commercialization of new active ingredients — including Isoflex® active, fluindapyr, Dodhylex® active and rimisoxafen — while optimizing resource allocation across businesses.

Pipeline seen as transformational opportunity

FMC emphasizes four newly developed actives and a broader development pipeline as distinctive, potentially transformative assets that could benefit from extra investment or different capital structures. Management signals that some assets may be prioritized for retention and expansion while others could be candidates for licensing or divestiture as part of the debt-reduction plan. The strategic review is therefore presented as a way to align balance-sheet repair with targeted investment in high-growth chemistries and market positions.

Guidance and near-term outlook

For full-year 2026, FMC provides revenue guidance of $3.60 billion to $3.80 billion, a midpoint decline of roughly 5% versus 2025, and says pricing is expected to be lower by mid-single digits largely due to the post-patent dynamics of Rynaxypyr®. The company plans to use asset sales and licensing to meet its deleveraging goal and to free capacity for pipeline commercialization.

Communications and next steps

FMC says it will discuss results and the strategic review on its upcoming earnings call and does not intend further comment unless additional disclosure becomes appropriate. The company reiterates that the review is ongoing and maintains its operational priorities while exploring potential options.